I am excited to announce Spiral have joined the team working on the first response adaptive platform trial to be based in Australia and New Zealand(REMAP-CAP). The self-learning design for this clinical trial is an exciting new methodology that significantly reduces the time and number of patients needed to test treatments while increasing safety for trial participants.

For this project our Spinnaker software will be used in Australian and New Zealand ICUs to test questions related to community acquired pneumonia.  Spinnakers adaptability is a key factor in this self-learning/adaptive trial.

Trial funding

The trial is funded by the Health Research Council of New Zealand(HRC) and the National Health and Medical Research Council of Australia(NHMRC).

General Characteristics of a Platform Trial

• A novel and innovative trial design that is highly adaptive and utilises frequent Bayesian interim analyses to answer as many questions as possible from the available sample

• Simultaneously evaluates the effectiveness of multiple alternative treatment options in a heterogeneous population including identifying any interactions between treatments

• Evaluates treatment effects in sub-groups

• Allows modification of key trial parameters in response to accumulated information and predefined rules

• Preferentially randomises participants to treatments that are likely to be more effective, leading to better outcomes for patients within the trial.